FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology

Presented at ASCO 2019, Chicago, Il, US

David Michael Hyman¹, Lipika Goyal², Petros Grivas³, Funda Meric-Bernstam⁴, Josep Tabernero⁵, Youyou Hu⁶, Yulia Kirpicheva⁶, Valerie Nicolas-Metral⁶, Anna Pokorska-Bocci⁶, Anne Vaslin⁶, Claudio Zanna⁶, Keith Flaherty^{2, 7}

1. Memorial Sloan Kettering Cancer Center, New York, NY;
2. Massachusetts General Hospital, Boston, MA;
3. University of Washington, School of Medicine, Seattle, WA;
4. The University of Texas MD Anderson Cancer Center, Houston, TX;
5. Vall d’Hebron University Hospital and Institute of Oncology, University Autònoma de Barcelona, Barcelona, Spain;
6. Debiopharm International SA, Lausanne, Switzerland;
7. Dana-Farber Cancer Institute/Harvard Medical School